| Autor: |
Du Feng, Huixin Jiang, Gengjia Chen, Wenhui Guan, Lin Yi, Yue Zhu, Yijia Li, Gengda Huang, Bin He, Junlong Tang, Yujie Tang, Jiyuan Zeng, Wensheng Zhou, Jiayu Shi, Zhanhong Xie, Ming Liu, Xiaohong Xie, Xinqing Lin, Chengzhi Zhou |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Frontiers in Immunology, Vol 15 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1664-3224 |
| DOI: |
10.3389/fimmu.2024.1485358 |
| Popis: |
The STK11 gene mutation is a common genetic alteration in non-small cell lung cancer (NSCLC) and is significantly associated with poor responses to current immunotherapy regimens. Despite its prevalence, there is currently no established standard for front-line treatment in this subtype of NSCLC, underscoring the increasing need for personalized therapeutic strategies. In this report, we present a case of a patient with STK11-mutant NSCLC who was treated with first-line cadonilimab (10mg/kg) in combination with pemetrexed (500mg/m^2) plus carboplatin (AUC=5), resulting in a notable extension of progression-free survival (PFS). This case highlights the potential efficacy and feasibility of combining immunotherapy with chemotherapy in patients with STK11-mutant NSCLC. Additionally, we provide a review of recent advancements in research related to STK11 mutations in lung cancer as reported in the literature. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
